Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04641143 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT04641143 is a Phase 3 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 456 participants.
The verdict
NCT04641143, a Phase 3 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Interventions
- DRUG Placebo
- DRUG Troriluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04641143
The ClinicalTrials.gov registry entry for NCT04641143 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04641143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04641143 about?
NCT04641143 is a clinical study titled "Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder". The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
What is the current status of trial NCT04641143?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2020-12-22. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT04641143?
The interventions under investigation include: Placebo (DRUG), Troriluzole (DRUG).
Who is sponsoring clinical trial NCT04641143?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.